Sensei Biotherapeutics Inc. has announced new retention agreements for President and Principal Executive Officer Christopher Gerry and Senior Vice President of Finance and Principal Finance and Accounting Officer Josiah Craver. Effective November 14, 2025, Gerry's annual base salary is set at $425,000 and Craver's at $400,000. Both executives are eligible for an annual target bonus equal to 40% of their base salaries beginning with the year ending December 31, 2026. Additionally, they are eligible for retention bonuses, including a full target annual bonus for 2025 if they remain employed through February 13, 2026, or are terminated without cause or resign for good reason before that date. A pro-rated target bonus for 2026 will also be available under certain termination conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sensei Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-331113), on December 23, 2025, and is solely responsible for the information contained therein.